These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cholinergic drugs in Alzheimer's disease. Davis KL; Mohs RC N Engl J Med; 1986 Nov; 315(20):1286-7. PubMed ID: 3773941 [No Abstract] [Full Text] [Related]
24. Peptide inhibitors of beta-amyloid aggregation. Doig AJ Curr Opin Drug Discov Devel; 2007 Sep; 10(5):533-9. PubMed ID: 17786851 [TBL] [Abstract][Full Text] [Related]
25. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease? Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173 [TBL] [Abstract][Full Text] [Related]
26. Partners in death.Alzheimer's protein rouses cell-suicide enzyme. Leslie M Sci Aging Knowledge Environ; 2004 Dec; 2004(48):nf106. PubMed ID: 15576819 [No Abstract] [Full Text] [Related]
27. Therapeutic strategies for Alzheimer's disease. Wolfe MS Nat Rev Drug Discov; 2002 Nov; 1(11):859-66. PubMed ID: 12415246 [TBL] [Abstract][Full Text] [Related]
29. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767 [TBL] [Abstract][Full Text] [Related]
30. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Refolo LM; Pappolla MA; LaFrancois J; Malester B; Schmidt SD; Thomas-Bryant T; Tint GS; Wang R; Mercken M; Petanceska SS; Duff KE Neurobiol Dis; 2001 Oct; 8(5):890-9. PubMed ID: 11592856 [TBL] [Abstract][Full Text] [Related]
31. The immune system, amyloid-beta peptide, and Alzheimer's disease. Weksler ME; Gouras G; Relkin NR; Szabo P Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358 [TBL] [Abstract][Full Text] [Related]
32. Advances in understanding the pathogenetic mechanisms of Alzheimer's disease. Govoni S; Lanni C; Racchi M Funct Neurol; 2001; 16(4 Suppl):17-30. PubMed ID: 11996513 [No Abstract] [Full Text] [Related]
33. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. McKinney M; Coyle JT Mayo Clin Proc; 1991 Dec; 66(12):1225-37. PubMed ID: 1749291 [TBL] [Abstract][Full Text] [Related]
34. Intracranial drug administration in Alzheimer's disease. Harbaugh RE Psychopharmacol Bull; 1986; 22(1):106-9. PubMed ID: 3726055 [No Abstract] [Full Text] [Related]
35. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Sugimoto H Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377 [TBL] [Abstract][Full Text] [Related]
36. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology. Silvestrelli G; Lanari A; Parnetti L; Tomassoni D; Amenta F Mech Ageing Dev; 2006 Feb; 127(2):148-57. PubMed ID: 16278007 [TBL] [Abstract][Full Text] [Related]